40 results
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
either might give rise to a conflict of interest or a conflict with any of your duties to the Company.
It is accepted and acknowledged that you have
8-K
EX-10.4
ADAP
Adaptimmune Therapeutics plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
circumstances, you may have to seek the Board's agreement before accepting further commitments which either might give rise to a conflict of interest
8-K
EX-10.3
ADAP
Adaptimmune Therapeutics plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
either might give rise to a conflict of interest or a conflict with any of your duties to the Company.
It is accepted and acknowledged that you have
8-K
EX-10.1
a0lr4
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
S-3ASR
oe6ptskrj9iu92eh
10 Aug 20
Automatic shelf registration
5:01pm
424B5
entj366dl1 pj6li3y0m
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
8uw2xvpxqvd83i4zj4ay
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-10.1
ejyw mb3zrot6zfmgl
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am